EMA Scrutinizes Ibuprofen’s Cardiovascular Risk Potential
This article was originally published in The Tan Sheet
Executive Summary
EMA’s Pharmacovigilance Risk Assessment Committee will recommend whether current contraindications, precautions and warnings relating to arterial thrombotic risk of ibuprofen at daily usage of 2,400 mg and up are adequate and whether updates to the product information or other regulatory measures are needed.